Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Common Equity (2016 - 2026)

Gyre Therapeutics has reported Common Equity over the past 16 years, most recently at $106.0 million for Q4 2025.

  • Quarterly Common Equity rose 7.75% to $106.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $106.0 million through Dec 2025, up 7.75% year-over-year, with the annual reading at $106.0 million for FY2025, 7.75% up from the prior year.
  • Common Equity was $106.0 million for Q4 2025 at Gyre Therapeutics, up from $101.9 million in the prior quarter.
  • Over five years, Common Equity peaked at $129.4 million in Q2 2025 and troughed at $13.9 million in Q4 2023.
  • The 5-year median for Common Equity is $85.2 million (2021), against an average of $79.6 million.
  • Year-over-year, Common Equity plummeted 80.68% in 2023 and then surged 605.44% in 2024.
  • A 5-year view of Common Equity shows it stood at $59.5 million in 2021, then increased by 21.44% to $72.2 million in 2022, then plummeted by 80.68% to $13.9 million in 2023, then surged by 605.44% to $98.4 million in 2024, then increased by 7.75% to $106.0 million in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Common Equity are $106.0 million (Q4 2025), $101.9 million (Q3 2025), and $129.4 million (Q2 2025).